TuHURA Biosciences (NASDAQ:HURA) Stock Rating Upgraded by Wall Street Zen

TuHURA Biosciences (NASDAQ:HURA) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.

A number of other brokerages have also recently issued reports on HURA. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of TuHURA Biosciences in a report on Tuesday, February 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $9.00.

TuHURA Biosciences Trading Down 3.6%

Shares of TuHURA Biosciences stock opened at $2.96 on Wednesday. TuHURA Biosciences has a 12-month low of $0.41 and a 12-month high of $4.44. The stock has a market cap of $188.19 million, a PE ratio of -4.70 and a beta of -0.32. The company has a 50-day moving average of $1.71 and a two-hundred day moving average of $1.62.

TuHURA Biosciences (NASDAQ:HURA) last issued its earnings results on Tuesday, March 31st. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01).

Institutional Trading of TuHURA Biosciences

Several large investors have recently modified their holdings of HURA. Geode Capital Management LLC grew its position in shares of TuHURA Biosciences by 111.4% in the second quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock valued at $1,300,000 after purchasing an additional 307,260 shares during the last quarter. Deutsche Bank AG grew its position in shares of TuHURA Biosciences by 209.8% in the fourth quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock valued at $61,000 after purchasing an additional 54,051 shares during the last quarter. New York State Common Retirement Fund acquired a new stake in shares of TuHURA Biosciences in the second quarter valued at approximately $97,000. Goldman Sachs Group Inc. acquired a new stake in shares of TuHURA Biosciences in the fourth quarter valued at approximately $30,000. Finally, Marshall Wace LLP acquired a new stake in TuHURA Biosciences during the second quarter worth approximately $79,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.